Picture of BioVie logo

BIVI BioVie Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-25.33%
3m+16.37%
6m+139.44%
1yr+48.56%
Volume Change (%)
10d/3m-64.04%
Price vs... (%)
52w High-65.09%
50d MA-23.15%
200d MA+35.55%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-162.77%
Return on Equity-236.37%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202330th Jun 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of BioVie EPS forecast chart

Profile Summary

BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Directors

Last Annual
June 30th, 2022
Last Interim
September 30th, 2022
Incorporated
April 10th, 2013
Public Since
January 14th, 2014
No. of Employees
13
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
32,477,397

BIVI Share Price Performance

Upcoming Events for BIVI

Similar to BIVI

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Aceragen logo

Aceragen

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email